{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:09:14Z","timestamp":1700179754684},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,16]]},"DOI":"10.1093\/bjd\/ljad328","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T18:54:45Z","timestamp":1694026485000},"page":"e101-e102","source":"Crossref","is-referenced-by-count":0,"title":["Risankizumab versus apremilast in the era of skin clearance"],"prefix":"10.1093","volume":"189","author":[{"given":"Emma","family":"Veysey","sequence":"first","affiliation":[{"name":"Dermatology Department, St Vincent\u2019s Hospital , Melbourne , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,9,6]]},"reference":[{"key":"2023111618472668800_ljad328-B1","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"2023111618472668800_ljad328-B2","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bjd.20818","article-title":"Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis","volume":"186","author":"Gordon","year":"2022","journal-title":"Br J Dermatol"},{"key":"2023111618472668800_ljad328-B3","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris \u2013 Part 1: treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J Eur Acad Dermatol and Venereol"},{"key":"2023111618472668800_ljad328-B4","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"5","author":"Sbidian","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2023111618472668800_ljad328-B5","doi-asserted-by":"crossref","first-page":"e14487","DOI":"10.1111\/dth.14487","article-title":"Efficacy and safety of risankizumab in moderate to severe psoriasis: a systematic review and meta-analysis","volume":"34","author":"Singh","year":"2021","journal-title":"Dermatol Ther"},{"key":"2023111618472668800_ljad328-B6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-\u00adsevere plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023111618472668800_ljad328-B7","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/bjd\/ljad252","article-title":"Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)","volume":"189","author":"Stein Gold","year":"2023","journal-title":"Br J Dermatol"},{"key":"2023111618472668800_ljad328-B8","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/bjd.18333","article-title":"Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)","volume":"182","author":"Mahil","year":"2020","journal-title":"Br J Dermatol"},{"key":"2023111618472668800_ljad328-B9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/13696998.2019.1571500","article-title":"Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis","volume":"22","author":"Wu","year":"2019","journal-title":"J Med Econ"},{"key":"2023111618472668800_ljad328-B10","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40273-016-0382-3","article-title":"Apremilast for the treatment of moderate to severe plaque psoriasis: a critique of the evidence","volume":"34","author":"Hinde","year":"2016","journal-title":"Pharmacoeconomics"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad328\/52763338\/ljad328.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/189\/6\/e101\/53474823\/ljad328.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/189\/6\/e101\/53474823\/ljad328.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T18:49:33Z","timestamp":1700160573000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/189\/6\/e101\/7261687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,6]]},"references-count":10,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,9,6]]},"published-print":{"date-parts":[[2023,11,16]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad328","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,9,6]]}}}